NIX CREME RINSE CREAM

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

şimdi satın al

Ürün özellikleri Ürün özellikleri (SPC)
06-12-2022

Aktif bileşen:

PERMETHRIN

Mevcut itibaren:

INSIGHT PHARMACEUTICALS, LLC

ATC kodu:

P03AC04

INN (International Adı):

PERMETHRIN

Doz:

1%

Farmasötik formu:

CREAM

Kompozisyon:

PERMETHRIN 1%

Uygulama yolu:

TOPICAL

Paketteki üniteler:

56 GM

Reçete türü:

OTC

Terapötik alanı:

SCABICIDES AND PEDICULICIDES

Ürün özeti:

Active ingredient group (AIG) number: 0120085001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2001-02-01

Ürün özellikleri

                                _Product Monograph _
_ _
_Page 1 of 16_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
NIX® CRÈME RINSE
PERMETHRIN CREAM 1%
Topical Pediculicide and Ovicide
ATC Code: P03AC04
Insight Pharmaceuticals LLC
660 White Plains Road, Suite 250
Tarrytown, NY 10591, USA
Date of Initial Authorization:
Apr 29, 2003
Date of Revision:
Dec 6, 2022
Submission Control Number: 263926
®Trademark
_ _
_Product Monograph _
_ _
_ _
_Page 2 of 16_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 4 DOSAGE AND ADMINISTRATION
01/2022
TABLE OF CONTENTS
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
.......................................................................................
4
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.3
Reconstitution
...................................................................................................
5
4.4
Administration
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Ürün özellikleri Ürün özellikleri Fransızca 06-12-2022

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin